
Sachet Ashok Shukla
@shuklasachet
ID: 440090489
18-12-2011 15:18:19
58 Tweet
133 Followers
40 Following

Very grateful to Kidney Cancer for the award, and to the amazing team (Chris Labaki Lisa Henske @shuklasachet Eli Van Allen Toni Choueiri, MD and others) as we try to better understand and treat this histology and beyond Yale Cancer Center Smilow Cancer Hospital


Dr Renee Maria Saliby super star Dana-Farber Lank Center for Genitourinary Oncology knocking it out of the park with her work with the molecular clusters in mRCC! Bravo! #KCRS22 David Braun Sachet Ashok Shukla Eli Van Allen #WCRM


Why chromophobe RCC is not immune-responsive? Chris Labaki is tackling this problem in a brilliant way !!!


Chris Labaki doing great microenvironment work Dana-Farber Lank Center for Genitourinary Oncology in chromophobe #kidneycancer. #KCRS22 KidneyCAN


Validation of RNA subgroups Brian Rini, MD and response data with axi/avelumab Renee Maria Saliby #kcrs22.Distribution across groups were the same as IM151. But axi/avelumab was better across all groups-unlike atezo/bev. Response within groups will be regimen specific



The Dana-Farber Lank Center for Genitourinary Oncology team at #KCRS22 with missing many !


First single-cell look at infiltrating immune cells in benign -> malignant renal oncocytic neoplasms jointly with #LisaHenske David Braun Toni Choueiri, MD Eli Van Allen led by Chris Labaki. Takeaway: less infiltrated, exhausted, non-specific T-cells in these tumors

Extremely grateful for the exceptional guidance of my mentors David Braun Eli Van Allen Toni Choueiri, MD , the collaboration with renowned scientists Lisa Henske Sachet Ashok Shukla , and the help from all team members in this project. This work would not have been possible without them.

Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology David Braun Sachet Ashok Shukla Eli Van Allen I can't thank you enough for giving me the opportunity to present this work (and for everything)


Great piece by Gina Kolata in NYT today about cancer vaccines. Preventive/early use of vaccines will be paradigm-shifting in the coming years. Grateful to be part of this story! nytimes.com/2022/10/10/hea…

🚨Hot off the press in Nature Medicine👉After KRAS G12C going after the next undruggable-KRAS G12D👉Anti-tumor efficacy of a potent & selective non-covalent KRAS G12D inhibitor 🎯🧬Huge implications in #precisionmedicine if translated to clinic @oncoalert go.nature.com/3ExqaoJ


Good morning! You've been asking -- here you go! #KCRS22 Video & Slides are up! · Video · Slides · Abstracts · Posters ➡️ bit.ly/WatchKCRS22 * Some slides/video are removed at the author's request. We will add when able. OncoAlert OncLive.com Targeted Oncology IKCC Kidney Cancer






1/ 🧵Excited to share our latest study published in Nature Cancer co-led with amazing co-first authors and friends Tejas Jammihal and Chris Labaki under the exceptional mentorship of Toni Choueiri, MD David Braun Sachet Ashok Shukla nature.com/articles/s4301…